TCR2 Therapeutics saw the highest growth of 99% in patent filings and 199% in grants in October in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 99% and grants by 199%. GlobalData’s DataBook provides a comprehensive analysis of TCR2 Therapeutics’s patent filings and grants. Buy the databook here.
TCR2 Therapeutics has been focused on protecting inventions in European Patent Office(EPO) with two publications in Q4 2023
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 25% filings and 0% grants. The European Patent Office(EPO), Denmark(DK), United States(US), and Israel(IL) patent Office are among the top ten patent offices where TCR2 Therapeutics is filings its patents. Among the top granted patent authorities, TCR2 Therapeutics has 67% of its grants in Israel(IL) and 33% in Poland(PL).
Patents related to rare diseases lead TCR2 Therapeutics's portfolio
TCR2 Therapeutics has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q4 2023.
Multiple sclerosis related patents lead TCR2 Therapeutics portfolio followed by polyradiculoneuropathy, and celiac disease
TCR2 Therapeutics has highest number of patents in multiple sclerosis followed by polyradiculoneuropathy, celiac disease, acquired (autoimmune) hemolytic anemia, and inflammation.
For comprehensive analysis of TCR2 Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.